Loana Musso

Also affiliated with Celsion (United States)

Biochemistry, Genetics and Molecular BiologyPharmacology, Toxicology and PharmaceuticsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)”.

105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)

ESMO Open(2025)10.1016/j.esmoop.2025.105233

N/A

0DataRank · unranked

1 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Bhavana Pothuri, Jennifer Scalici +14 more